ArticleVeterinary research communications2025
Unveiling the role of Alcea rosea in modulating growth, immunity, antioxidant defenses, and gene expression in zebrafish (Danio rerio).
Article in Veterinary research communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Novel and natural alternative feed ingredients are essential for sustainable aquaculture sector. For a period of 60 days, this study examined the effects of incorporating Hollyhock (Alcea rosea) powder into the diet on gene expressions, growth parameters, serum biochemical and innate immune parameters, as well as antioxidant capacity in zebrafish (Danio rerio). Fish, with an initial weight of (302.66 ± 3.75) mg, were seperated into four groups. Each group was fed a diet containing varying percentages of Hollyhock: 0% (AR0), 0.5% (AR05), 1% (AR1), and 2% (AR2). Growth performance was significantly enhanced in the AR2 group, with no significant differences observed in the other groups. The supplementation of Hollyhock led to significant alterations in the serum biochemical parameters, specifically alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP), resulting in notably lower levels compared to the AR0 group. The Hollyhock-supplemented diet led to a significant increase in both total protein and total immunoglobulin levels, as compared to the AR0 group. There were no changes observed in CAT activity related to antioxidant defense, while exclusive to the AR05 group, a substantial elevation was observed in SOD activity compared to the AR0 group. The results shown that the expression levels of growth-related genes, such as GH and IGF-1, showed an increase in all diets supplemented with Hollyhock. Growth exhibited a statistically significant difference in group AR2, while no significant difference was observed in the other groups. The Heat Shock Protein 70 gene (HSP70) was downregulated specifically in the AR1 group. Immune-related genes, including LYZ, IL-1β, and TNF, were significantly upregulated with Hollyhock supplementation. Both LYZ and TNF showed the highest expression in the AR1 and AR2 groups, while IL-1β peaked in the AR1 group. In terms of antioxidant-related genes, Antioxidant-related genes, SOD and CAT, were significantly upregulated in Hollyhock-treated groups. SOD expression peaked in the AR1 group, and CAT was most upregulated in the AR1 and AR2 groups. Overall, these results suggest that supplementation with 1-2% Hollyhock in the diet of zebrafish positively influenced growth, immunity, antioxidant defense, and serum biochemical parameters, making it a promising feed additive for enhancing aquaculture productivity and fish health.
Indexed as
Identifiers
39954150What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.